Search Results | NIH

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Search Results 2461 – 2480 of 3231

Bacterial Enteric Infections

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/bacterial-enteric

Discontinuation or Interruption of Antiretroviral Therapy

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/discontinuation-or-interruption-antiretroviral-therapy

Cryptosporidiosis

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/cryptosporidiosis

Cystoisosporiasis (Formerly Isosporiasis)

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/cystoisosporiasis

Fixed-Dose Combinations

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-arv/fixed-dose-combinations

Etravirine (Intelence, ETR)

https://clinicalinfo.hiv.gov/guidelines/perinatal/safety-toxicity-arv-agents-nnrtis-etravirine-intelence

Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors (NRTIs)

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-arv/nucleoside-and-nucleotide-analogue-reverse

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/zidovudine

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/figures

Drug-Drug Interactions: Nucleoside Reverse Transcriptase Inhibitors and Other Drugs

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/drug-interactions-nrti

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/toxoplasmosis

Pharmacoenhancers

https://clinicalinfo.hiv.gov/guidelines/perinatal-hiv-clinical-guidelines/pharmacoenhancers

Ritonavir (Norvir, RTV)

https://clinicalinfo.hiv.gov/guidelines/perinatal/safety-toxicity-arv-agents-pharmacoenhancers-ritonavir-norvir

Pregnancy and Postpartum HIV Testing and Identification of Perinatal and Postnatal HIV Exposure

https://clinicalinfo.hiv.gov/guidelines/perinatal/maternal-hiv-testing-identification-exposure

https://clinicalinfo.hiv.gov/guidelines/perinatal/archived-drugs-overview

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/indinavir

Laboratory Testing for Initial Assessment and Monitoring of People With HIV

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/tests-initial-assessment-follow-up

Special Populations

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/special-populations

Special Populations: Substance Use Disorders and HIV

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/special-populations-substance-use-disorders

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/tables